p63 expression as a new prognostic marker in Mrkel cell carcinoma

Cancer

Volumn 110, Issue 3, 2007, Pages 640-647

  Asioli, Sofia ^a   Righi, Alberto ^b   Volante, Marco ^a   Eusebi, Vincenzo ^b   Bussolati, Gianni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ki 67 MIB 1; Merkel cell carcinoma; p53; p63; Prognosis

Indexed keywords

CHROMOGRANIN A; CYTOKERATIN 20; KI 67 ANTIGEN; PROTEIN P63; SYNAPTOPHYSIN;

ARTICLE; CELL DIFFERENTIATION; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ELDERLY CARE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MERKEL CELL TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SKIN TUMOR;

AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; CHROMOGRANIN A; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-20; KI-67 ANTIGEN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34547104216     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22828     Document Type: Article

References (40)

1. Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972;105:107-110.
2. Frigerio B, Capella C, Eusebi V, Tenti P, Azzopardi JG. Merkel cell carcinoma of the skin: the structure and origin of normal Merkel cells. Histopathology. 1983;7:229-249.
3. Brinkschmidt C, Stolze P, Fahrenkamp AG, et al. Immunohistochemical demonstration of chromogranin A, choromoganin B, and secretoneurin in Merkel cell carcinoma of the skin: an immunohistochemical study on 18 cases suggesting two types of Merkel cell carcinoma. Appl Immunohistochem. 1995;3:37-44.
4. Chen SY, Gerson S, Meyer J. The fusion of Merkel cells granules with a synapse-like structure. J Invest Dermatol. 1973;61:290-292.
5. Sibley RK, Rosai J, Foucar E, et al. Neuroendocrine (Merkel cell) carcinoma of the skin. Am J Surg Pathol. 1980;4:211-221.
6. Urbatsch A, Sams WM Jr, Urist MM, Sturdivant R. Merkel cell carcinoma occurring in renal transplant patients. J Am Acad Dermatol. 1999;41:289-291.
7. LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006.
8. DiComo CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissue. Clin Cancer Res. 2002;8:494-501.
9. Lo Muzio L, Santarelli A, Caltabiano R, et al. p63 overxpression associates with poor prognosis in head and neck squamous carcinoma. Hum Pathol. 2005;36:187-194.
10. Kalhor N, Zander DS, Liu JT. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously papstained cytologic material. Mod Pathol. 2006;19:1117-1123.
11. Takeuchi Y, Tamura A, Kamida M, Fukuda T, Ishikawa O. Immunohistochemical analysis of p63 expression in cutaneous tumours. Br J Dermatol. 2005;153:1230-1232.
12. Hu H, Xia SH, Li AD, et al. Elevated expression of p63 protein in human esophageal squamous cell carcinoma. Int J Cancer. 2002;102:580-583.
13. Koker MM, Kleer CG. p63 expression in breast cancer. Am J Surg Pathol. 2004;28:1506-1512.
14. Comperat E, Camparo P, Haus R, et al. Immunohistochemical expression of p63, p53, MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch. 2006;448:319-324.
15. Wang TY, Chen BF, Yang YC, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol. 2001;32:479-486.
16. Signoretti S, Waltregny D, Dilks J, et al. P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157:1769-1775.
17. Foschini MP, Gaiba A, Cocchi R, et al. Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch. 2004;444:332-339. Epub 2004 Mar 2.
18. Lo Muzio L, Santarelli A, Caltabiano R, et al. p63 expression correlates with pathological features and biological behaviour of odontogenetic tumours. Histopathology. 2006;49:211-214.
19. Marucci G, Betts CM, Liguori L, et al. Basaloid carcinoma of the pancreas. Virchows Arch. 2005;446:322-324.
20. Fukushima N, Satoh T, Sueoka N, et al. Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci. 2006;97:1-6.
21. Yiengpruksawan A, Coit DG, Thaler HT, et al. Merkel cell carcinoma: prognosis and management. Arch Surg. 1991;126:1514-1519.
22. McCarthy KS, Miller LS, Cox EB, Konrath J, McCarthy KS Sr. Estrogen receptor analysis: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-721.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Cox D. Regressions models and life table. J R Stat Soc. 1972;34:187-220.
25. Koljonen V, Bohling T, Granhroth G, Tuiainen E. Merkel cell carcinoma: a clinicopathological study of 34 cases. Eur J Surg Oncol. 2003;29:607-610.
26. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United states. J Am Acad Dermatol. 2003;49:832-841.
27. Mott RT, Smoller BR, Morgan MB. Merkel cell carcinoma: a clinicopathologic study with prognostic implication. J Cutan Pathol. 2004;31:217-223.
28. Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol. 1997;37:734-739.
29. Benessahraoui M, Dalstein V, Lorchel F, et al. Merkel cell carcinoma: descriptive study of 24 cases (1993-2001). Rev Med Interne. 2003;24:560-568.
30. Carson HJ, Reddy V, Taxy JB. Proliferation markers and prognosis in Merkel cell carcinoma. J Cutan Pathol. 1998;25:16-19.
31. Pilate M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope. 1992;102:244-249.
32. Ott MJ, Tanabe KK, Gadd MA, et al. Multimodality management of Merkel cell carcinoma. Arch Surg. 1999;134:388-393.
33. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300-2309.
34. Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beeken SW. Multimodality treatment of Merkel cell carcinoma: case series and literature reviewed. Ann Surg Oncol. 2001;8:204-208.
35. Llombart B, Monteagudo C, Lopez-Guerrero JA, et al. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology. 2005;46:622-634.
36. Sandel HD 4th, Day T, Richardson MS, Scarlet M, Gutman KA. Merkel cell carcinoma: does tumor size or depth of invasion correlate with recurrence, metastasis, or patient survival? Laryngoscope. 2006;116:791-795.
37. Fernandez-Figueras MT, Puig L, Musulen E, et al. Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extra-cutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. Histopathology. 2005;46:614-621.
38. Erickson LA, Papotti M, Volante M, Jin L, Lewis JE, Lloyd RV. Merkel cell carcinomas: expression of S-phase kinase-associated protein (Skp2), p27, and proliferation markers. Endocr Pathol. 2003;14:221-229.
39. Parrado C, Bjornhagen V, Eusebi V, et al. Prognosticating tools in primary neuroendocrine (Merkel-cell) carcinomas of the skin: histopathological subdivision, DNA cytometry, cell proliferation analysis (ki-67-immunoreactivity) and NCAM immunohistochemestry. A clinicopathological study in 25 patients. Pathol Res Pract. 1998;194:11-23.
40. Koljonen V, Tukiainen E, Haglund C, Bohling T. Proliferative activity detected by Ki67 correlated with poor outcome in Merkel cell carcinoma. Histopathology. 2006;49:551-553.